← All companies

LBRX

LB Pharmaceuticals Inc

LBRX Nasdaq Pharmaceutical Preparations EDGAR ↗

$42.84

+1.94 +4.74%

Key statistics

from XBRL data in SEC filings

Market cap

$1.23B

Revenue (TTM)

—

Net income (TTM)

-$39.0M

EPS (TTM)

$-3.13

P/E ratio

—

Dividend yield

—

Free cash flow

-$35.3M

Cash

$321M

Total assets

$393M

Gross margin

—

52-week range

$13.36 – $44.33

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Jul 29, 2026 8-K Other events Jul 22, 2026 8-K Director or officer change Jun 10, 2026 8-K Shareholder vote results Jun 9, 2026 10-Q Quarter ended 2026-03-31 May 12, 2026 8-K Results of operations (earnings release) May 12, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Results of operations (earnings release) Mar 26, 2026 8-K Director or officer change Mar 16, 2026 8-K Director or officer change; Regulation FD disclosure Mar 10, 2026 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure; Other events Feb 5, 2026 8-K Entered a material agreement Nov 13, 2025 8-K Other events Nov 12, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Amended charter or bylaws Sep 12, 2025

Other filings

4 Aug 3, 2026 SCHEDULE 13G/A Jul 29, 2026 424B3 Jul 29, 2026 424B3 Jul 22, 2026 SCHEDULE 13G Jul 16, 2026 424B3 Jun 10, 2026 144 Jun 9, 2026 424B3 Jun 9, 2026 4 Jun 5, 2026 4 Jun 5, 2026 4 Jun 5, 2026 4 Jun 5, 2026 4 Jun 5, 2026 4 Jun 5, 2026 4 Jun 5, 2026 SCHEDULE 13G/A May 15, 2026 SCHEDULE 13G/A May 15, 2026 SCHEDULE 13G May 15, 2026 SCHEDULE 13G/A May 13, 2026 424B3 May 12, 2026 ARS Apr 23, 2026 DEFA14A Apr 23, 2026 DEF 14A Apr 23, 2026 EFFECT Apr 14, 2026